

Supplementary Table I: Amino Acid Sequence of Trastuzumab IgE

Heavy Chain Amino Acid Sequence: Herceptin VH3 and Cepsilon Constant Region

```
0 EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR
50 IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG
100 GDGFYAMDYW GQGTLVTVSS ASTTQSPSVF PLTRCCKNIP SNATSVTLGC
150 LATGYFPEPV MVTWDTGSLN GTTMTLPATT LTLSGHYATI SLLTVSGAWA
200 KQMFTCRVAH TPSSTDWVDN KTFSVCSRDF TPPTVKILQS SCDGGGHFPP
250 TIQLLCLVSG YTPGTINITW LEDGQVMDVD LSTASTTQEG ELASTQSELT
300 LSQKHWLSDR TYTCQVTYQG HTFEDSTKCC ADSNPRGVSA YLSRPSPFDL
350 FIRKSPTITC LVVDLAPSKG TVNLTWSRAS GKPVNHSTRK EEKQRNGTTL
400 VTSTLPVGRD DWIEGETYQC RVTHPHLPRA LMRSTTKTSG PRAAPEVYAF
450 ATPWPGSRD KRTLACLIQN FMPEDISVQW LHNEVQLPDA RHSTTQPRKT
500 KGSQFFVFSR LEVTRAEWEQ KDEFICRAVH EAASPSQTVQ RAVSVNPGK
```

Light Chain Amino Acid Sequence: Variable and Kappa Constant Light Chain Region

```
0 DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS
50 ASFLYSGVPS RFGSGRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ
100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
150 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
200 LSSPVTKSFN RGEC
```

**Supplementary Table II:
ADCC/ADCP Assay Data**

<i>Figure 3c</i>		Trastuzumab IgG (n = 6)	
		% ADCC ± SD	% ADCP ± SD
No ab		8.9 ± 4.4	8.1 ± 1.8
MOv18 IgG 0.5µg/ml		9.8 ± 5.9	8.1 ± 1.8
Trastuzumab IgG 0.05µg/ml		10.7 ± 1.8 (n/s)(n/s)	17.2 ± 9.7 (*) (*)
Trastuzumab IgG 0.5µg/ml		14.7 ± 3.1 (*) (n/s)	17.6 ± 9.2 (*) (*)
Trastuzumab IgG 5µg/ml		8.9 ± 5.1 (n/s)(n/s)	20.5 ± 6.3 (**)(**)


<i>Figure 4c</i>		Trastuzumab IgE (n = 5)	
		% ADCC ± SD	% ADCP ± SD
No ab		7.8 ± 2.9	7.0 ± 3.7
MOv18 IgE 0.5µg/ml		8.9 ± 4.8	7.7 ± 4.2
Trastuzumab IgE 0.05µg/ml		15.0 ± 5.8 (n/s)(n/s)	8.2 ± 4.3 (n/s)(n/s)
Trastuzumab IgE 0.5µg/ml		22.4 ± 8.5 (*) (*)	8.5 ± 4.6 (n/s)(n/s)
Trastuzumab IgE 5µg/ml		19.2 ± 7.7 (*) (*)	8.4 ± 5.9 (n/s)(n/s)

<i>Figure 6a</i>		Trastuzumab IgG (n = 5)	
		% ADCC ± SD	% ADCP ± SD
No ab		10.9 ± 2.8	12.8 ± 4.3
MOv18 IgG 0.5µg/ml		14.6 ± 4.9	9.6 ± 5.3
Trastuzumab IgG 0.5µg/ml		14.2 ± 7.8 (n/s) (n/s)	25.1 ± 2.5 (**)(***)

<i>Figure 6b</i>		Trastuzumab IgE (n = 5)	
		% ADCC ± SD	% ADCP ± SD
No ab		9.5 ± 2.3	7.4 ± 4.0
MOv18 IgE 0.5µg/ml		6.6 ± 1.1	6.2 ± 2.0
Trastuzumab IgE 0.5µg/ml		23.2 ± 4.9 (**)(***)	12.9 ± 3.4 (*) (*)

Significance compared to samples given no antibody (left stars) and MOv18 IgG/IgE (right stars) by the Student's *t*-test: (n/s)*P* > 0.05, (*)*P* < 0.05, (**)*P* < 0.005, (***)*P* < 0.0005.

Supplementary Figure 1: MTS Assay



Cell viability assays (MTS) demonstrating levels of susceptibility of CT26-HER2/*neu* tumour cells to trastuzumab and MOv18 IgG antibodies at 4, 24 and 48 hours in culture. Each data point represents mean % cell viability \pm SD ($n = 5$).